Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review
Archives of Gynecology and Obstetrics · 2025
DOI: 10.1007/s00404-024-07905-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Archives of Gynecology and Obstetrics, 2025. Verfasst von Svitlana Arbuzova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Eastern-Ukrainian Center for Medical Genetics and Prenatal Diagnosis, Mariupol, Kiev, Ukraine. Hauptthemen laut MEDLINE: Pre-Eclampsia, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Academy, Tel Aviv University.
Abstract (Originalsprache)
Purpose
To quantify the separation between maternal blood cell-free (cf)DNA markers in preeclampsia and unaffected pregnancies and compare with existing markers. This approach has not been used in previous studies.
Methods
Comprehensive systematic literature search of PubMed to identify studies measuring total cfDNA, fetal cf(f)DNA or the fetal fraction (FF) in pregnant women. Included—studies of asymptomatic pregnancies with subsequent preeclampsia (cases) and unaffected pregnancies (controls) tested in the first or second trimester and before the clinical onset of preeclampsia. Excluded—studies not reporting the median or mean, standard deviation, inter-quartile range or range in cases and controls. Information from 26 eligible studies was entered into a meta-analysis to estimate, for each marker, the Mahalanobis distance, a measure of separation between the overlapping distributions in preeclampsia and unaffected pregnancies. This was compared with estimates for mean arterial pressure (MAP), uterine artery Doppler pulsatility index (UtA-PI), pregnancy associated plasma protein (PAPP)-A and placental growth factor (PlGF).
Results
The mean Mahalanobis distance for total cfDNA was 0.44 (95% CI 0.12–0.76), which fell between UtA-PI (0.53) and the absolute value of PAPP-A (– 0.36). For cffDNA the distance was 1.03 (0.37–1.69), which is superior to MAP (0.74), UtA-PI, PlGF (– 0.57) and PAPP-A. The distance for FF was – 0.34 (– 0.56 to – 0.12), similar to PAPP-A.
Conclusion
All three markers have a potential preeclampsia screening role, particularly cffDNA. However, to estimate the screening performance in combination with existing markers further large studies are needed. The current analysis will help in the power calculation for such studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eastern-Ukrainian Center for Medical Genetics and Prenatal Diagnosis, Mariupol, Kiev, Ukraine.
- Institute of Health Research, University of Exeter, Exeter, UK.
- Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. h.s.cuckle@leeds.ac.uk.
ORCID-Profile: Svitlana Arbuzova, Howard Cuckle
Förderung
- British Academy
- Tel Aviv University
Zitieren
APA
Arbuzova, S., & Cuckle, H. (2025). Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-024-07905-4
Vancouver
Arbuzova S, Cuckle H. Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review. Archives of Gynecology and Obstetrics. 2025. doi:10.1007/s00404-024-07905-4
BibTeX
@article{Arbuzova2025,
author = {Arbuzova, Svitlana and Cuckle, Howard},
title = {Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
doi = {10.1007/s00404-024-07905-4}
}
EUVIMED